Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial | Zendy

Phanthaboon Wangpatharawanit | Zendy; Somnuek Sungkanuparph | Zendy

Open Access

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial

Author(s) -

Phanthaboon Wangpatharawanit,

Somnuek Sungkanuparph

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw395

Subject(s) - ritonavir , atazanavir , lopinavir , medicine , lopinavir/ritonavir , atorvastatin , randomized controlled trial , pharmacology , virology , human immunodeficiency virus (hiv) , gastroenterology , viral load , antiretroviral therapy

A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research